Lantheus Q3: Revenue $389.9M, $31M IPR&D Impairment, Cash Builds to $683.6M
LNTH has more than doubled off its 52-week low of $50.155.
Summary
Lantheus reported Q3 revenue of $389.9 million (+1.5%) with GAAP EPS down 19.5% to $0.33 on $31.0 million of IPR&D impairments and $24.3 million of approval milestone charges, while cash rose to $683.6 million. Guidance stays suspended pending the $102.50-per-share Curium merger, now under an FTC Second Request.
Key Events · Earnings and Guidance · LNTH
-
Q3 Revenue Flat at $389.9M
Worldwide revenue rose 1.5% to $389.9 million from $384.0 million, as PYLARIFY slipped 0.7% to $238.9 million while Neuraceq climbed 123.0% to $45.6 million.
-
$31M IPR&D Impairment Hits R&D
Q3 R&D expense jumped 93.2% to $92.8 million, including $21.0 million and $10.0 million impairments on LNTH-2620 and LNTH-2515 plus $14.3 million TAUKLARIFY and $10.0 million BRAVNETSA milestone charges.
-
Cash Builds to $683.6M
Cash and equivalents reached $683.6 million at September 30, 2026 from $359.1 million at year-end, helped by $319.3 million of nine-month operating cash flow and a $59.4 million gain on the SPECT sale.
-
FTC Second Request Extends Merger Review
The October 21, 2026 FTC Second Request extends the HSR waiting period; Lantheus and Curium still expect to close the $102.50-per-share cash plus up to $12.00 CVR deal in the first half of 2027.
Analysis · LNTH · Life Sciences
The top line was roughly flat, with revenue up 1.5% to $389.9 million, but earnings quality was worse than that suggests. GAAP diluted EPS fell 19.5% to $0.33 as R&D jumped 93.2% to $92.8 million, driven by $31.0 million of IPR&D write-downs (LNTH-2620 and LNTH-2515) and $24.3 million of approval milestone charges for TAUKLARIFY and BRAVNETSA. The balance sheet strengthened against that backdrop: cash reached $683.6 million from $359.1 million at year-end on $319.3 million of nine-month operating cash flow and the SPECT sale. With the $102.50-per-share Curium deal pending and guidance suspended, the operating numbers matter less than the FTC review — the October 21 Second Request extends the HSR waiting period, and closing is still targeted for the first half of 2027.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LNTH was trading at $100.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $50.16 to $111.86. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.